Amgen Stock Price - AMGN

213.08
-1.46 (-0.68%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Amgen Inc AMGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
4.16 1.98% 214.54 212.02 216.70 216.18 210.38 20:00:00
Bid Price Ask Price Spread Spread % News
210.00 216.86 6.86 3.16% - 4
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
39,898 3,313,975 $ 214.92 $ 712,235,331 2,408,576 165.06 - 247.9999
Last Trade Time Type Quantity Stock Price Currency
19:06:00 1 $ 213.08 USD

Amgen Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 126.54B 589.81M $ 8.39B 12.89 17.20 586.89M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 287.27% 02/13/20 - -

more financials information »

Amgen News

Date Time Source News Article
2/26/202015:40Dow Jones NewsAmgen Shares Up, Will Continue Phase 3 Heart Failure Trial
2/26/202010:04Dow Jones NewsAmgen, Cytokinetics to Continue Phase 3 Heart Failure Trial
2/26/202008:30GlobeNewswire Inc.Amgen, Cytokinetics and Servier Announce Continuation of..
2/26/202008:30PR Newswire (US)Amgen, Cytokinetics And Servier Announce Continuation Of..
2/21/202016:21Edgar (US Regulatory)Current Report Filing (8-k)
2/20/202006:01Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(2) (424b2)
2/18/202017:29Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules..

Latest AMGN Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AMGN Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week222.94224.05209.82217.382,351,425-8.40-3.77%
1 Month225.50235.00209.82222.492,441,996-10.96-4.86%
3 Months232.73247.9999209.82231.882,157,628-18.19-7.82%
6 Months200.60247.9999188.78218.172,250,17113.946.95%
1 Year189.56247.9999165.06199.402,544,71324.9813.18%
3 Years174.21247.9999152.16186.582,933,82540.3323.15%
5 Years158.48247.9999130.08174.112,990,03256.0635.37%

Amgen Description

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering) and Aimovig (migraine).
Your Recent History
NASDAQ
AMGN
Amgen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200227 01:49:50